Promoting innovation while controlling cost: The UK's approach to health technology assessment
Open Access
- 28 January 2022
- journal article
- research article
- Published by Elsevier in Health Policy
- Vol. 126 (3) , 224-233
Abstract
No abstract availableKeywords
This publication has 64 references indexed in Scilit:
- Comparison of treatment effect sizes associated with surrogate and final patient relevant outcomes in randomised controlled trials: meta-epidemiological studyBMJ, 2013
- Commonalities and differences in HTA outcomes: A comparative analysis of five countries and implications for coverage decisionsHealth Policy, 2012
- NICE guidance: a comparative study of the introduction of the single technology appraisal process and comparison with guidance from Scottish Medicines ConsortiumBMJ Open, 2012
- Who Does the Numbers? The Role of Third-Party Technology Assessment to Inform Health Systems' Decision-Making about the Funding of Health TechnologiesValue in Health, 2009
- QALYs: Some ChallengesValue in Health, 2009
- Writing narrative literature reviews for peer-reviewed journals: secrets of the tradeJournal of Chiropractic Medicine, 2006
- Providing guidance to the NHS: The Scottish Medicines Consortium and the National Institute for Clinical Excellence comparedHealth Policy, 2006
- Orphan drugs and the NHS: should we value rarity?BMJ, 2005
- Contradicted and Initially Stronger Effects in Highly Cited Clinical ResearchJAMA, 2005
- Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosisBMJ, 2003